NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
SAN DIEGO Nov. 14, 2024 /PRNewswire/ -- Neurelis, Inc. ("Company"), today announced a transaction with OrbiMed for the sale of the Company's rights, royalty interests, and related sales milestone payments on global net sales of neffy® (nasal epinephrine) (the "Neffy Receivables"). Neurelis, through its subsidiary Aegis Therapeutics, LLC ("Aegis"), previously entered into an agreement with ARS Pharmaceuticals, Inc. ("ARS") for the Neffy Receivables. In this new transaction, OrbiMed agreed to purchase 100% of the Company's rights and interests in the Neffy Receivables for an aggregate purchase price of $208 million "Entering this agreement with OrbiMed will simplify our balance sheet and provide cash flow to advance our existing programs for therapeutics targeting epilepsy and neurological disorders," said Craig Chambliss , Neurelis Founder and CEO. "This transaction, yet again, demonstrates the tremendous value in the INTRAVAIL® platform, in enabling first in class/best in class the
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United StatesGlobeNewswire
- ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 11/13/24 - Miss
SPRY
Sec Filings
- 11/14/24 - Form 4
- 11/14/24 - Form 4
- 11/13/24 - Form 4
- SPRY's page on the SEC website